Trading in Marinus Pharma halted pending news

|About: Marinus Pharmaceuticals (MRNS)|By:, SA News Editor

Nasdaq has stopped trading in micro cap Marinus Pharmaceuticals (NASDAQ:MRNS) pending news.

The company's lead product candidate is Phase 3-stage ganaxolone for the adjunctive treatment of focal onset seizures in adult patients.

Subscribe for full text news in your inbox